Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
McKesson
Boehringer Ingelheim
Merck
Moodys

Last Updated: May 17, 2022

TOSYMRA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Tosymra, and what generic alternatives are available?

Tosymra is a drug marketed by Upsher Smith Labs and is included in one NDA. There are seven patents protecting this drug.

This drug has seventy patent family members in twenty-one countries.

The generic ingredient in TOSYMRA is sumatriptan. There are twenty-four drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the sumatriptan profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tosymra

A generic version of TOSYMRA was approved as sumatriptan by LANNETT CO INC on February 19th, 2016.

  Try it Free

Summary for TOSYMRA
International Patents:70
US Patents:7
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 2
Formulation / Manufacturing:see details
Drug Prices: Drug price information for TOSYMRA
What excipients (inactive ingredients) are in TOSYMRA?TOSYMRA excipients list
DailyMed Link:TOSYMRA at DailyMed
Drug patent expirations by year for TOSYMRA
Drug Prices for TOSYMRA

See drug prices for TOSYMRA

US Patents and Regulatory Information for TOSYMRA

TOSYMRA is protected by seven US patents.

Patents protecting TOSYMRA

Formulations comprising triptan compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE

Alkylglycoside compositions for drug administration
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Compositions for drug administration
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE

Formulations comprising triptan compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE

Compositions for drug administration
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Formulations comprising triptan compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE

Formulations comprising triptan compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upsher Smith Labs TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Upsher Smith Labs TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Upsher Smith Labs TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Upsher Smith Labs TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Upsher Smith Labs TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TOSYMRA

See the table below for patents covering TOSYMRA around the world.

Country Patent Number Title Estimated Expiration
Japan 2012513412 See Plans and Pricing
European Patent Office 3678649 FORMULATIONS D'ÉPINÉPHRINE INTRANASALE ET MÉTHODES DE TRAITEMENT D'UNE MALADIE (INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE) See Plans and Pricing
World Intellectual Property Organization (WIPO) 2011036521 See Plans and Pricing
European Patent Office 2480197 FORMULATIONS COMPRENANT DES COMPOSÉS TRIPTAN (FORMULATIONS COMPRISING TRIPTAN COMPOUNDS) See Plans and Pricing
United Kingdom 2587934 Intranasal epinephrine formulations and methods for the treatment of disease See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
McKesson
Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.